Navigation Links
Avastin, Sutent increase breast cancer stem cells, U-M study shows
Date:1/25/2012

ANN ARBOR, Mich. Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't lead to longer survival, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

The drugs Avastin and Sutent have been looked at as potential breast cancer treatments. But while they do shrink tumors and slow the time till the cancer progresses, the effect does not last, and the cancer eventually regrows and spreads.

"This study provides an explanation for the clinical trial results demonstrating that in women with breast cancer antiangiogenic agents such as Avastin delay the time to tumor recurrence but do not affect patient survival. If our results apply to the clinic, it suggests that in order to be effective, these agents will need to be combined with cancer stem cell inhibitors, an approach now being explored in the laboratory," says study author Max S. Wicha, M.D., director of the U-M Comprehensive Cancer Center.

The researchers treated mice with breast cancer using Avastin (bevacizumab) and Sutent (sunitinib), both of which work by stopping the growth and formation of blood vessels, a process called angiogenesis. The researchers found that tumors treated with these drugs developed more cancer stem cells, the small number of cells within a tumor that fuel a cancer's growth and spread and that are often resistant to standard treatment. Both the number of cancer stem cells and the percentage of cancer stem cells that make up the tumor increased after being treated with each of these therapies.

The researchers found that the cancer stem cells increased because of a cellular response to low oxygen, a condition called hypoxia. And they were able to determine the specific pathways involved in hypoxia that activate the cancer stem cells.

Results of the study appear online in the Proceedings of the National Academy of Sciences Early Edition.

The U.S. Food and Drug Administration recently revoked approval of Avastin for treating breast cancer, although the drug is approved for use in other types of cancer. The reversal was in response to clinical trials showing that the drug's benefit was short-lived, with breast cancer patients quickly relapsing and the cancer becoming more invasive and spreading further throughout the body. Overall, the drug did not help patients live any longer.

The current study suggests the possibility of combining anti-angiogenesis drugs with a cancer stem cell inhibitor to enhance the benefit of this treatment. The researchers are testing this approach in mice and preliminary data looks promising.

Breast cancer statistics: 209,060 Americans will be diagnosed with breast cancer this year and 40,230 will die from the disease, according to the American Cancer Society


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Governor Rendell Proposes Budget With No Tax Increase, More Money for Public Schools, Strategy for Jobs, Plan to Address Future Deficits
2. Soft drinks may increase risk of pancreatic cancer
3. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
4. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
5. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
6. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
9. Migraine Linked to Increased Heart Attack Risk
10. Anthem Blue Cross of California Agrees to Request From California Department of Insurance for Additional Time to Re-Review Rate Increase
11. Anthem Blue Crosss Announcement That It Will Temporarily Suspend a 39% Health Insurance Rate Increase Should Not Deter Immediate Legislative Action
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin, Sutent increase breast cancer stem cells, U-M study shows
(Date:4/29/2016)... ... April 29, 2016 , ... A new study by a ... diaphragmatic hernia have better survival rates if surgery is performed early. Approximately one ... the diaphragm fails to form completely, letting abdominal organs into the chest cavity ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only ... majority of skin cancer deaths. More than 10,000 people are expected to die of melanoma ... 62, it is the one of the most commonly diagnosed cancers in young women. A ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Reltok Nasal ... and products for the head and neck/ear, nose and throat specialty, has added the ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations ... Inc. in an upcoming episode, airing third quarter 2016 via Discovery Channel. Dates ... into butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies product research and ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... PARIS , April 29, 2016 ... Jérôme Contamine, Directeur Financier ... la santé, publie ses résultats pour ... Financier du Groupe, Jérôme Contamine, commente ... Groupe et les perspectives pour le ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)... Ind., April 28, 2016 , Net Sales ... reported basis over the prior year period, and an increase ... , Diluted EPS for the first quarter were $0.52 ... and $2.00 adjusted, an increase of 29.9% over the prior ... and adjusted earnings guidance for 2016 Zimmer Biomet ...
Breaking Medicine Technology: